Eagle Pharmaceuticals and Enalare Therapeutics Announce FDA Orphan Drug Designation for ENA-001 for the Treatment of Apnea of Prematurity, a New Chemical Entity Being Developed as an Agnostic Respiratory Stimulant

Eagle Pharmaceuticals, Inc. announced that the FDA had granted Orphan Drug Designation to ENA-001 for the treatment of Apnea of Prematurity, a new chemical entity with a novel mechanism of action as a respiratory stimulant.